Market Overview:
The global acute myeloid leukemia (AML) therapeutics market is expected to register a CAGR of 7.8% during the forecast period, 2018-2030. The market growth can be attributed to factors such as increasing incidence of AML, rising demand for better treatment options, and technological advancements in the field of oncology. Based on type, the chemotherapy segment is expected to account for the largest share of the global AML therapeutics market in 2018. This can be attributed to increasing use of chemotherapy as a first-line treatment option for AML patients. Based on application, hospitals are expected to account for the largest share of the global AML therapeutics market in 2018. This can be attributed to increasing number of hospital admissions owing to rising incidence rate of AML across the globe.
 Therapeutics Industry Outlook.svg)
Product Definition:
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. In AML, the bone marrow produces too many immature white blood cells called blasts. These blasts can crowd out healthy cells and prevent the bone marrow from making enough red blood cells, white blood cells, and platelets.
Chemotherapy:
Chemotherapy is the use of drugs or chemical substances to treat cancer. Chemotherapy includes a group of medical procedures used to control or reduce the symptoms and side effects caused by cancer. The most common types of chemotherapy include alkylating agents, cytotoxic agents, antimetabolites, plant derivatives ( taxanes ), and others.
Radiation therapy:
Radiation therapy is the use of ionizing radiation in cancer treatment. Ionizing radiation has two types of effects, namely, direct and indirect. Direct effect includes damage to DNA and RNA, which leads to mutations; whereas indirect effect refers to damage caused by radiotherapy equipment or materials.
Application Insights:
The acute myelogenous leukemia (AML) treatment market by application is segmented into hospital, clinics, and others. The hospital segment dominated the market in 2017 owing to availability of a large number of hospitals that offer specialized AML care. Moreover, increasing prevalence of cancer and growing aging population are expected to drive this segment over the forecast period.
Clinics are anticipated to witness significant growth over the forecast period due largely to rising awareness about early diagnosis and effective treatment options for patients with limited financial resources or who cannot travel long distances from their homes due to work commitments or other obligations. Increasing cases of chronic diseases such as heart diseases, diabetes mellitus type 2 & 3 across regions coupled with high patient acceptance towards new technology treatments are some factors expected drive this segment in near future.
Regional Analysis:
North America dominated the global market in 2017. Key factors responsible for its large share include the presence of key players, such as Celgene Corporation; Pfizer Inc.; and AbbVie, Inc. Moreover, these companies are engaged in extensive R&D activities to develop novel drugs that can be used for treatment of acute myeloid leukemia (AML). For instance, in May 2018, Pfizer entered into a collaboration with Uppsala University to discover and develop new targets and therapies for blood diseases. The company will also provide funds worth USD X million over 10 years to the researchers at Uppsala University.
Growth Factors:
- Increasing incidence of AML
- Rising demand for better treatment options for AML patients
- Growing awareness about AML and its treatment options
- Technological advancements in the field of AML therapeutics
- Availability of government funding for research on new AML therapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Acute Myeloid Leukemia (AML) Therapeutics Market Research Report
By Type
Chemotherapy, Radiation therapy, Stem Cell Transplant, Targeted Therapy, Others
By Application
Hospital, Clinics, Others
By Companies
Bristol-Myers Squibb, Novartis, Roche, Genmab, GlaxoSmithKline Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
193
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global Acute Myeloid Leukemia (AML) Therapeutics Market Report Segments:
The global Acute Myeloid Leukemia (AML) Therapeutics market is segmented on the basis of:
Types
Chemotherapy, Radiation therapy, Stem Cell Transplant, Targeted Therapy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb
- Novartis
- Roche
- Genmab
- GlaxoSmithKline Pharmaceuticals
 Therapeutics Market Overview.svg)
Highlights of The Acute Myeloid Leukemia (AML) Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Radiation therapy
- Stem Cell Transplant
- Targeted Therapy
- Others
- By Application:
- Hospital
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Acute Myeloid Leukemia (AML) Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Therapeutics Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Acute myeloid leukemia (AML) is a type of cancer that starts in the white blood cells, called lymphocytes. These cells help the body fight infection and disease. AML can occur in any age group, but is most common in adults over 50 years old.
Some of the major players in the acute myeloid leukemia (aml) therapeutics market are Bristol-Myers Squibb, Novartis, Roche, Genmab, GlaxoSmithKline Pharmaceuticals.
The acute myeloid leukemia (aml) therapeutics market is expected to grow at a compound annual growth rate of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Acute Myeloid Leukemia (AML) Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Acute Myeloid Leukemia (AML) Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Acute Myeloid Leukemia (AML) Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Acute Myeloid Leukemia (AML) Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size & Forecast, 2020-2028
4.5.1 Acute Myeloid Leukemia (AML) Therapeutics Market Size and Y-o-Y Growth
4.5.2 Acute Myeloid Leukemia (AML) Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Chemotherapy
5.2.2 Radiation therapy
5.2.3 Stem Cell Transplant
5.2.4 Targeted Therapy
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Acute Myeloid Leukemia (AML) Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Acute Myeloid Leukemia (AML) Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Chemotherapy
9.6.2 Radiation therapy
9.6.3 Stem Cell Transplant
9.6.4 Targeted Therapy
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Chemotherapy
10.6.2 Radiation therapy
10.6.3 Stem Cell Transplant
10.6.4 Targeted Therapy
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Chemotherapy
11.6.2 Radiation therapy
11.6.3 Stem Cell Transplant
11.6.4 Targeted Therapy
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Chemotherapy
12.6.2 Radiation therapy
12.6.3 Stem Cell Transplant
12.6.4 Targeted Therapy
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Chemotherapy
13.6.2 Radiation therapy
13.6.3 Stem Cell Transplant
13.6.4 Targeted Therapy
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Acute Myeloid Leukemia (AML) Therapeutics Market: Competitive Dashboard
14.2 Global Acute Myeloid Leukemia (AML) Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol-Myers Squibb
14.3.2 Novartis
14.3.3 Roche
14.3.4 Genmab
14.3.5 GlaxoSmithKline Pharmaceuticals
